

Dofetilide Initiation and Implications of Deviation From the Standard Protocol – A Real World Experience

Tawseef Dar¹, Ghulam Murtaza², Bharath Yarlagadda³, Bader Madoukh², Lesley Bravin⁴, Venkat Vuddanda⁵, Valay Parikh⁴, Madhu Reddy⁴, Dhanunjaya Lakkireddy².

¹Department of Nuclear Cardiology, Massachusetts General Hospital, Boston, MA.

²Kansas City Heart Rhythm Institute & Research Foundation, Overland Park, KS.

³Division of Cardiology, University of New Mexico, Albuquerque, NM.

⁴Division of Cardiovascular Diseases, University of Kansas Hospital & Medical Center, Kansas City, KS.

⁵Department of General Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Abstract

Background: Manufacturer/federal drug administration (FDA) recommends inpatient initiation of dofetilide with the manufacturer providing an initiation algorithm. The outcomes of algorithm deviation have not been reported outside of clinical trials.

Objective: We sought to perform a chart review of all the patients admitted for inpatient initiation of dofetilide to report on the incidence of protocol deviations and their implications.

Methods: We performed a retrospective review of all patients over a 15-month period who were initiated on dofetilide for the very first time or reinitiated on dofetilide after a break of three months or more at our institution. We assessed data about patients who were given dofetilide without adherence to the protocol (i.e. protocol deviation).

Results: A total of 189 patients were included in the study with a median age of 66 ± 9 years. Mean baseline QTc interval was 436 ± 32 msec, and 61% (116/189) were in atrial fibrillation (AF) at the time of dofetilide initiation. In 9% (17/189) of patients, the drug was discontinued due to intolerance or inefficacy. Therapy in 49% (93/189) of patients was noted to deviate from manufacturer recommended protocol with deviations more than once in some patients during the same hospitalization. Baseline QTc exceeding 440 msec (>500msec in conduction abnormalities) was the most frequent deviation (25%; 47/189). Ventricular tachyarrhythmia occurred in 4% (7/189) of patients, did not differ between patients, and occurred with and without protocol deviations (5% vs 2%; p = 0.27).

Conclusions: In our retrospective study, there were frequent deviations from the manufacturer-recommended algorithm guidelines for dofetilide initiation, primarily due to prolonged baseline QTc interval. The impact of these protocol deviations on drug discontinuation was uncertain; however, significant adverse events were higher in the deviation group compared to the group that fully adhered to the protocol. Further multicenter studies are warranted to clarify our findings.

Introduction

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. Treatment involves medications to control either the rate while in AF or to pursue a rhythm control strategy to maintain sinus rhythm. Although clinical trials have not revealed a mortality benefit of rhythm control strategy versus rate control strategy¹⁻³, some patients are extremely symptomatic while in AF and a rhythm control strategy is necessary for these patients. Rhythm control strategy is the current standard of care when rate control is ineffective or patient is symptomatic despite controlled ventricular response⁴. AF leads to negative remodeling of the atria⁵ and sinus rhythm restoration,

aside from symptomatic improvement, has been shown to reverse the process of remodeling and therefore break the vicious circle⁶. In addition, AF, with rates poorly controlled despite use of maximal doses of AV nodal blocking agents, leads to tachycardia-mediated cardiomyopathy and ultimately congestive heart failure (CHF), making rhythm control strategy more suitable, especially in young patients⁷. One study of antiarrhythmic drug (AAD) therapy showed that patients who received dofetilide had a significantly higher probability of remaining in sinus rhythm up to 1 year compared to those who received placebo, even though there was no benefit in all-cause mortality.⁸ Sinus rhythm can be restored via pharmacologic or electrical cardioversion and can be maintained with use of AAD. AAD continue to remain the first line maintenance therapy and are often utilized to facilitate conversion from AF to sinus rhythm⁹.

Key Words

Dofetilide, Atrial fibrillation, Protocol, Deviation.

Corresponding Author

Dhanunjaya Lakkireddy, MD, FACC, FHRS
Executive Medical Director
The Kansas City Heart Rhythm Institute (KCHRI) @ HCA MidWest
Professor of Medicine, University of Missouri, Columbia, MO
12200, W 106th street, Overland Park Regional Medical Center
Overland Park, KS 66215

Amiodarone is the most potent antiarrhythmic agent but is associated with significant side effects most of which are non-cardiac. Dofetilide, a class III antiarrhythmic agent, blocks rapid component of delayed rectifier potassium current (IKr) inhibitor channels and

is associated with minimal non-cardiac side effects. It increases action potential duration due to delayed repolarization and prolongs QT interval as a result of prolongation of effective and functional refractory period of the His-Purkinje system and the ventricles. Dofetilide is moderately effective in converting AF to sinus rhythm but exhibits 58% efficacy in maintaining sinus rhythm at the end of one year¹⁰. The package insert pertaining to dofetilide specifies that in patients with supraventricular arrhythmias, the incidence of TdP at dosing <250mcg BID is 0%, at 250mcg BID is 0.3%, at >250-500mcg BID is 0.9%, and at >500mcg is 10.5%. As a result, the FDA, at the time of initial approval of dofetilide in 1999, mandated that dofetilide could only be started in patients after administering the initial 5 doses over three days in the inpatient setting with continuous EKG monitoring.

Furthermore, in July 2011, the FDA released a detailed protocol for initiation of dofetilide suggesting the starting dose and appropriate dosage changes depending on the changes in QTc post initiation and creatinine clearance. The adherence to this protocol and the consequences of deviation are unknown. Outside of the clinical trials involving dofetilide, there is very little data from the real-world experience regarding the frequency of protocol deviations and their outcomes.

Hence, we performed an observational study including patients who were admitted to our hospital for dofetilide initiation with an emphasis on patients whose therapy deviated from the manufacturer recommended protocol.

Methods

Study Population

Upon getting approval from the Institutional Review Board, we performed a retrospective review of all patients, over a 15-month period, who were initiated on dofetilide for the very first time or reinitiated on dofetilide after a break of three months or more at our institution. Patients were included if there was documentation of an EKG with QTc at baseline and two hours after each dose. Patients with long QT syndrome or prior history of cardiopulmonary resuscitation due to any cause were excluded from the study. Every attempt was made to discontinue all prior antiarrhythmics for a period amounting to five half-lives of respective drugs.

Dosing

Patients were dosed as per University of Kansas Hospital Pharmacy protocol for inpatient initiation of dofetilide and the protocol was executed via an electronic order set which is in line with the FDA/manufacturer's recommendations. Doses were mainly based on the initial QTc (or QT interval if heart rate was <60 beats/minute) and creatinine clearance as shown in [Figure 1].

Protocol Deviations

Protocol implementation was overseen by the pharmacy team. Every attempt was made to encourage compliance with the protocol. Any violation of FDA recommended dosing algorithm at any stage was considered a deviation from protocol [Figure 1]. Efforts were made to detect those patients who received dofetilide not in

accordance with the protocol.

Data collection and Study outcomes

From the chart review, we collected baseline demographic information, medical history, baseline laboratory blood test results, including creatinine clearance, electrolytes, EKG information pre- and post-dofetilide initiation, direct current cardioversion, and pharmaceutical interventions.

The primary outcome of the study was to evaluate the incidence of deviations from FDA-recommended protocol for inpatient dofetilide initiation in clinical practice. Secondary outcomes included incidence of intolerance/inefficacy leading to drug discontinuation, need for electrical cardioversion, and incidence of ventricular tachyarrhythmia specifically in patients in whom there was a protocol deviation.

Definitions

Drug Intolerance: Symptomatic drug adverse effects including symptomatic proarrhythmias; symptomatic adverse effects eg: headache, dizziness, nausea, back pain, and abdominal pain; laboratory abnormality including QT prolongation but without symptoms leading to physician directed drug discontinuation.

Serious adverse event (SAE): Any ventricular tachyarrhythmia read as Torsades de pointes, ventricular fibrillation, or sustained ventricular tachycardia was classified as a serious adverse event.

Statistical Analysis

Continuous variables are expressed as mean \pm standard deviation (SD) if variables are normally distributed, and median (interquartile range) when deviations from normality were present. Categorical variables are expressed as counts and percentages. Categorical variables were compared between the groups using chi-squared test or fisher's exact test. Continuous variables were compared using independent sample t test. A two tailed p value less than 0.05 was considered statistically significant. Binary logistic regression model was used to determine factors related to serious adverse events. Statistical analysis was performed using IBM SPSS Statistics version 23.0 (IBM, Armonk, New York).

Table 1: Demographics and other clinical variables of the overall study population.

Variable	Dofetilide Initiation (Total N=189) n (%)
Demographics	
Female/Male	69 (37%) / 120 (63%)
Median age in years \pm SD	66 \pm 9 (34-86)
Obese (ABW > 40% IBW)	77 (41%)
Medical History	
Hypertension	95 (50%)
Coronary artery disease	54 (29%)
Ischemic cardiomyopathy	35 (19%)
CHF or EF < 40%	27 (14%)
Creatinine Clearance	
\geq 60 mL/min	164 (87%)
Serum Electrolytes	
Median potassium (range) in mEq/L	4.3 (3.3-5.1)
Median magnesium (range) in mEq/L	1.9 (1.3-2.5)
Electrocardiogram	
Mean baseline QTc (range) in msec \pm SD (range)	436 \pm 32 (349-530)
In AF or AFI upon initiation	116 (61%)

AF= atrial fibrillation; AFI= atrial flutter; ABW= adjusted body weight; IBW= ideal bodyweight

Table 2: Protocol deviations encountered during Dofetilide loading.

Types of deviations from manufacturer recommended guidelines	No. of patients n (%)
1. Dofetilide initiation with an elevated baseline QTc > 440 msec (or > 500 msec in conduction abnormalities)	47 (25)
2. QTc interval > 500 msec anytime after the 2nd dose without subsequent discontinuation of dofetilide therapy	35(18.5)
3. Increase of QTc interval > 15% above baseline post 1st dose without subsequent dofetilide dose reduction	16 (8.5)
4. Antiarrhythmic drug interaction at time of initiation (patients who were previously on amiodarone or dronedarone and had shorter washout periods than recommended)	13 (7)

Table 3: Demographics and clinical characteristics of deviation and non-deviation groups.

Characteristics	Deviation Group (n=93)	No Deviation Group (n=96)	P value
Demographics			
Mean Age	66 ± 8.3	65±9.4	0.12
Gender-Male	60 (65%)	60 (62.5%)	0.68
Female	33 (35%)	36 (37.5%)	
Comorbidities			
LVEF <40%	15 (16%)	12 (12.5%)	0.42
Heart rate <60 at initiation	20 (16.8%)	3 (4.3%)	0.01
Open heart surgery in last 2 months	1 (0.8%)	0 (0%)	0.447
MI or unstable angina in the past	5 (5%)	0	0.086
AF upon initiation	67 (72 %)	49(51%)	0.054
Creatinine clearance	82 ±17	80±20	0.93
Serious adverse event	4 (4%)	1 (1 %)	0.20
Drug discontinuation rate	12 (13%)	6 (6%)	0.14
QTc interval at discharge in msec	435 ± 26	428± 19	0.66

n (%) or mean ± SD; LVEF= left ventricular ejection fraction; MI= myocardial infarction

2% had a QTc of more than 500 msec at baseline. There was a 19% (35/189) prevalence of a baseline ventricular conduction abnormality.

Chemical vs electrical cardioversion


Of the 116 patients who presented in AF or AFL, 65% (75/116) required direct current cardioversion while being treated with dofetilide. Overall, 50% (94/189) of patients required electrical cardioversion at some point while in the hospital secondary to AF persistence. At the time of discharge, 11% (20/189) of patients were not in sinus rhythm despite attempts at electrical or chemical cardioversion. In addition, 10% (18/189) were brought back for a repeat attempt at electrical cardioversion 1-2 weeks later, of whom 6% (11/189) had successful electrical cardioversion, with drug discontinuation occurring in 4% (7/189) of patients.

Deviation from protocol

Therapy in 49% (93/189) of patients was noted to deviate from manufacturer-recommended protocol with some of the patients deviating more than once, in different ways, during the same hospitalization. The reasons for deviations are listed in [Table 2]. Baseline QTc exceeding 440 msec (>500msec in patients with conduction abnormalities) was the most frequent deviation (25%; 47/189), followed by QTc interval > 500 msec anytime after the second dose without subsequent discontinuation of dofetilide therapy (18.5%; 35/189) [Figure 2].

Dofetilide dosing and QTc prolongation

QTc prolongation (>500msec) was present in 18.5% of patients after getting the second dose, but only two of those patients had persistently prolonged QTc at the completion of loading dose in whom the drug was discontinued. The prolongation of QTc interval >15% occurred in 8.5% of patients after the first dosing but without significant issues



*in patients with ventricular conduction abnormality

Figure 1: Dofetilide dosing algorithm (FDA approved/ Manufacturer recommended).

Results

Baseline characteristics (AF vs Sinus rhythm)

Baseline characteristics of the 189 patients included in the study are shown in [Table 1]. Mean age was 66 ± 9 years (range 34 – 86 years), and 63 % (n=120/189) were males. Hypertension, coronary artery disease, and cardiomyopathy were seen in 50 % (n=95/189), 29 % (54/189) and 19% (35/1189) of patients, respectively. Severe cardiomyopathy (left ventricular ejection fraction <35%) was seen in 14% (27/189) of patients. The majority of patients (164/189, 87%) had a creatinine clearance ≥ 60 mL/min, calculated using the Cockcroft Gault formula. At the time of dofetilide initiation, 61 % (116/189) were in AF or AFL. Mean baseline QTc interval was 436 ± 32 msec (range 349–530 msec). With regard to the distribution of patients among various QTc intervals, 66% (125/189) of patients had a QTc ≤ 440 msec, 32% (61/189) had a QTc of 441-500 msec, and




Figure 2: Bar chart diagram showing different types of deviations.

during the subsequent dosing and at time of discharge. None of these patients needed drug discontinuation. Even though 6.5% of patients did not have thorough drug washout from other AADs, there was no significant impact on QTc and/or subsequent clinical outcomes. Post chemical or electrical cardioversion, the QTc intervals at the time of discharge were within the normal limits.

Drug discontinuation and Adverse events (Deviation vs non deviation group)

Overall, dofetilide therapy was discontinued in 9% (18/189) of patients secondary to inefficiency or drug intolerance. The rate of drug discontinuation for “deviation group” was 13% (12/93) vs 6% (6/96) for “non-deviation” group ($p = 0.14$). A total of 11 patients (torsades de pointes in five following prolonged QTc, non-sustained ventricular tachycardia in two, and QT prolongation without torsades de pointes in four) had drug intolerance leading to drug discontinuation. The overall incidence of SAEs was 2.6% (5/189). The rate of SAE was 4% (4/93) in “deviation group” vs 1% (1/96) in “non-deviation group” (p value = 0.20). One patient in the deviation group had a baseline QTc of 530 msec and developed ventricular fibrillation while being monitored in the hospital. Interestingly, out of 5 patients with SAEs, 4 had QTc >500 milliseconds at one point after the second dose, but only 1 had continued the drug despite such QTc prolongation. There were only two patients who had a baseline QTc >440 msec (including one with baseline QTc >500). Comparison of baseline characteristics

of the two groups is shown in [Table 3].

Of note, in patients with severe cardiomyopathy (ejection fraction <35%), deviation was encountered in more than half of the patients (55%, 15/27) with only 1 (3.7%, 1/27) SAE reported.

Discussion

AAD continue to remain the first-line maintenance therapy after cardioversion to sinus rhythm. However, most of the available antiarrhythmic drugs are associated with serious cardiac and/or non-cardiac side effects like arrhythmias, QT prolongation, and liver or lung toxicities. Dofetilide is one of these antiarrhythmic drugs indicated for maintenance of sinus rhythm (Class 1A recommendation) based on reports from several trials like SAFIRE-D (Symptomatic Atrial Fibrillation Investigative Research on Dofetilide) trial¹⁰ and DIAMOND (Danish Investigations on Arrhythmia and Mortality on Dofetilide) study¹². However, due to risk of dose-dependent QT prolongation and serious arrhythmias, including torsades de pointes, the FDA has mandated that dofetilide initiation take place in the inpatient setting under continuous monitoring following the set protocol per manufacturer [Figure 2]. Despite its favorable side effect profile compared to other antiarrhythmic drugs, dofetilide is still being used as a second or third line drug by most cardiologists¹³. The reason for such practice could be prerequisites like inpatient initiation as well as strict protocol guidelines per manufacturer. Of

note, dofetilide is available in only a few countries outside of the U.S., and the restrictions on its use are different from restrictions in the U.S.

We completed a retrospective review of patients who underwent dofetilide initiation at our center and looked at various parameters during initiation to see how strictly cardiologists were following the manufacturer protocol, and to discern the implications of protocol deviations. We found that almost half of the patients (49%, 93/189) had a deviation from the protocol, and some patients had recurrent deviation during their initiation process.

The most common deviation from the protocol was elevated baseline QTc (>440 msec or >500 msec if ventricular conduction abnormality was present) followed by continuation of the drug despite a measured QTc >500 msec (or >550 msec if ventricular conduction abnormality present) any time after the second dose. The overall incidence of serious arrhythmias was 2.6%, which is the same rate reported in previous studies (SAFIR-D). Similarly, the SAE rate in patients with severe cardiomyopathy is the same as reported in DIAMOND study¹². The mean baseline QTc in most of these patients was 436 msec. There were individual variations in the QTc cut-off values with which each of the prescribers were comfortable. Oftentimes, an accurate QTc interval may be difficult to calculate due to the presenting rhythm of AF and AT, despite correction algorithms based on the rhythm. Unless the QTc is grossly abnormal, borderline QTc intervals above 440 msec may still clinically do well.

The inherent limitations in accurate QTc interval measurement when patients are in AF or AFL may lead to overestimation of QTc. The 440msec cut off may not be valid entirely based on real world experience. Unless the QTc is grossly abnormal, a lot of patients can have dofetilide initiation and subsequent cardioversion to be able to accurately measure QTc. Some of the standard protocol numbers used are mostly arbitrary and supported by historical data. These guidelines should be updated periodically based on real world data. Prospective drug registries can help answer a lot of these questions.

Limitations

Our study was conducted in a single center and was retrospective in nature. The reasons cited by the physicians for drug initiation despite protocol deviation were not reported. Of all the enrolled patients, 39% of patients who had a protocol deviation were in normal sinus rhythm; accurate QTc measurement in these cases would not have been difficult. A larger multi-center registry for dofetilide loading and maintenance would be helpful in better understanding the real-life implications and for better defining the loading parameters and variability in dosing among patients with varying baseline characteristics. Lastly, despite protocols in place to facilitate adherence, some providers did not adhere to the protocol due to personal preference and experience. Methods to emphasize better protocol adherence and documentation are needed.

Acknowledgments

None

Conclusion

Our single center experience with dofetilide initiation showed that deviations from protocols are routinely encountered. However, the implications of most of these deviations on drug discontinuation need further elucidation, and the group that had protocol deviations had significantly more serious adverse events compared to the group that had complete protocol adherence. The protocol for dofetilide initiation may need some revision pending further robust data. Larger multicenter studies are needed to better delineate our findings.

References

- Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U, Investigators S. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. *Journal of the American College of Cardiology* May 21 2003;41:1690-1696.
- Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial Fibrillation Follow-up Investigation of Rhythm Management I. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* Dec 5 2002;347:1825-1833.
- Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. *Lancet* Nov 25 2000;356:1789-1794.
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation* Dec 02 2014;130:2071-2104.
- Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* Oct 1 1995;92:1954-1968.
- Thomas L, Boyd A, Thomas SP, Schiller NB, Ross DL. Atrial structural remodelling and restoration of atrial contraction after linear ablation for atrial fibrillation. *Eur Heart J* Nov 2003;24:1942-1951.
- Cosio FG, Aliot E, Botto GL, Heidebuchel H, Geller CJ, Kirchhof P, De Haro JC, Frank R, Villacastin JP, Vijgen J, Crijns H. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. *Europace* Jan 2008;10:21-27.
- Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. *Circulation* Jul 17 2001;104:292-296.
- Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. *Arch Intern Med* Apr 10 2006;166:719-728.
- Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB, Jr. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. *Circulation* Nov 07 2000;102:2385-2390.
- Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. *JAMA* Apr 23-30 2003;289:2120-2127.
- Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ. Dofetilide in patients with

- congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. *N Engl J Med* Sep 16 1999;341:857-865.
13. Turagam MK, Afzal MR, Reddy M, et al. Practice variation in the re-initiation of dofetilide: An observational study. *Int J Cardiol* Jun 01 2017;236:221-225.